BRUSSELS – The contraceptive pill is the best known and also the most used contraceptive in Belgium and the Netherlands.(1,2) However, many women are thinking about switching to another method, especially women currently using birth control pill.(3) This is evident from a study that healthcare company Organon has commissioned among 2,000 women by research agency IPSOS.
When it comes to contraceptive methods (and other types of protection) the methods to choose from are increasing, but most women between the ages of 18 and 44 in Belgium and the Netherlands mainly use oral contraception, followed by the condom.(2) The IPSOS study shows that 4 out of 10 women consider using another contraception method in the future, especially women who are currently using the contraceptive pill.3) These women prefer long-acting reversible contraception, according to the majority of women in question.(4)
A method that was the best solution at the initial stage no longer has to be the way a few years later. In an issue of Topic Talks gynecologist and director of Ellesie, Els van Doorn, emphasizes that continuing on autopilot is not always the best way to go. “Investigate together with your healthcare provider whether your contraceptive method is still the right one. Many women don’t think about it enough, but with the right birth control you can improve your quality of life and feel happier. (5)
“In the choice (of contraception), the woman is leading,” emphasizes gynecologist Annette ter Haar, also in Topic Talks. “Some women are opposed to oral contraception but open to other forms of birth control.” (6)
It is important that women receive sufficient and correct information to be able to make their choice properly. They can always contact a healthcare professional: women in the Netherlands and Belgium usually select a contraceptive method after consultation with their general practitioner (especially in the Netherlands) or gynecologist (in Belgium). (7) In addition, information from independent websites can be useful in decision making, such as:
Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on March 8 as a day to recognize the growing health disparities women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognizes the need for a global effort to address her health and is starting with its own employees by providing paid time off this year to attend to their own health needs.
Research shows that the corona crisis is hitting women harder than men. In addition to unemployment and poverty, women are also more burdened privately by crisis and the measures taken, conclude HealthyWomen and the Dutch SER after research by, among others, McKinsey. In a survey, 78% of women said they usually put their own healthcare needs, such as scheduling doctor’s appointments, aside to focus on taking care of their family and other priorities.
“Organon launched with a commitment to listen to the needs of women and as part of our research, we learned that women are finding it harder than ever to make the time to care for even their most basic health needs,” said Kevin Ali, chief executive officer, Organon. “As a company investing in innovation to improve women’s health, I felt a responsibility to address this within our own global community of almost 9,500 employees.
”Petra Willems, Managing Director Organon Benelux, adds: “This year, the symbolic action we are taking is to encourage all our employees (men and women) to spend a day off to make a commitment to their own health and/or the health of the women in their lives. Whether that’s thinking about how you can improve your health or relaxing for a day. This includes more than 2,000 employees of Organon at the production sites and offices in the Benelux countries.”
By improving the understanding of women’s health needs, we are one step closer to eliminating the inequity gap. Organon invites organizations in The Netherlands, Belgium and Luxembourg and across the globe to join in raising awareness of the inequity in women’s health and to adopt initiatives that help women prioritize their health.
JERSEY CITY – Organon (NYSE: OGN) today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health.
Forendo, based in Finland, is pioneering the translation of intracrinology science into first-in-class therapeutic solutions. Intracrinology enables physicians to address diseases on an unprecedented tissue-specific level. Forendo’s programs are targeting endometriosis and polycystic ovarian syndrome (PCOS).
“Organon is dedicated to delivering medically significant women’s healthcare interventions, prioritizing disease areas based on her unmet needs. Endometriosis is among our highest priority areas of focus,” said Kevin Ali, Organon’s Chief Executive Officer. “Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.”
Organon earlier announced the acquisition of Alydia Health (that focuses on postpartum hemorrhage, PPH) and the fact that Organon and ObsEva are entering an agreement whereby Organon will license the global development, manufacturing and commercial rights to a potential treatment for preterm labor.
OSS – Almost one hundred years ago, in 1923, Salomon (Saal) van Zwanenberg founded NV Organon in the town of Oss in the Dutch province of North Brabant. Organon was the first company in Europe to market a substance as an effective medicine for treating diabetes. Over the years, an extensive selection of hormone-based drugs followed, including the contraceptive pill, introduced in 1962, which is probably the best known. Thanks to this product, Organon became a world player in the pharmaceutical industry and an important economic driver for the region.
As you walk through the grounds at Organon’s site almost a century later, you still see much that reminds you of the company’s former glory, in addition to new buildings. That tradition is often just skin-deep: hyper-modern laboratories and production facilities nestle behind the dark brown brick façades and stained-glass windows. Wenny Raaijmakers, the current site manager of Organon Oss, is proud of the organization’s rich legacy. “But the new Organon really is a very different company,” she says.
BRUSSELS – This week the Organon Benelux organization welcomed a EUCAN team for an inspiring internal business exchange meeting. The team, headed by regional president Nico van Hoecke, discussed opportunities and challenges in our local markets with the Benelux leadership team. Highlight of the two-day visit was the official opening of our Brussels office, by Nico van Hoecke and Benelux managing director Petra Willems, together with Benelux colleagues.
The very next day, an Organon delegation visited the Minister-President of Flanders, Jan Jambon (at the right on the photo), and advisor Karel Boutens, to whom we introduced Organon.
In a positive and constructive meeting, Petra Willems (managing director Organon Benelux, second from right), François Marivoet (site manager Organon Heist) and Annemieke de Groot (Organon Benelux External Affairs, second from left) highlighted Organon’s investments in (women’s) health, our contribution to employment and the economy and the need for technically skilled personnel for the production facility in Heist-op-den-Berg.
BRUSSELS – In the context of World Heart Day, we published a video with prof. dr. Angela Maas (cardiologist and professor of Cardiology for Women, Radboud UMC). She has been drawing attention to the specific challenges of the female heart for 30 years. “Cardiology has been developed from the male perspective. And we have learned over the past decades that this is not the way that we have to treat women”, she says in the video which you can watch on this page.
Watch the video with Angela Maas below. Subtitles Dutch and English are available via the CC button.
BRUSSELS – A survey among women (16-44 years) in Belgium shows a high rate of unplanned pregnancy. As a global women’s health company, Organon aims to raise awareness and ignite a worldwide conversation about the staggering rates of unplanned pregnancy around the world and in Belgium.
“While we have seen a lot of progress in the area of reproductive health, the rates of unplanned pregnancy around the world continue to be high”, says Petra Willems, Managing Director Organon Benelux. Worldwide, unplanned pregnancy impacts approximately 121 million women each year.10) A 2019 study reported that globally, more than 1 billion women have a need for family planning, but for 270 million of them, the need for modern methods of family planning is unmet.11)
An online survey conducted this month by Research Without Barriers (commissioned by Organon) among a thousand women in Belgium aged 16 to 44 shows that half have experienced an unplanned pregnancy while using contraception. Most of the women were under the age of 30 at the time.1) In the Netherlands and the United Kingdom, the figures are much lower. The same survey among one thousand Dutch women between the ages of 16 and 44 shows that a quarter have had an unplanned pregnancy.4) In the United Kingdom this is 31 percent.7) Unplanned pregnancy can impact any woman anywhere, regardless of her social or economic background.
Major impact An unplanned pregnancy can have a major impact on women’s lives. In Belgium, according to the survey, a quarter of women are happy with the unexpected pregnancy, but most women in the study indicate negative consequences.2) You can think of a relationship break-up, anxiety and stress or a feeling of failure towards family or parents. We also see similar negative consequences in surrounding countries such as the Netherlands5) and the United Kingdom8), but there the number of women who are happy with the unplanned pregnancy appears to be higher: 43 and 45 percent respectively. Of the women surveyed who experienced an unplanned pregnancy, a quarter opt for an abortion, according to the survey.
In Belgium3) and the Netherlands6), about 1 in 3 women surveyed appears to be satisfied with the current form of contraception, while in the United Kingdom this is slightly higher at 45 percent9). In general, the women surveyed are open to another form of contraception. More information about contraception (methods) in general and help with making a choice can be found on the website of the Flemish expertise centre for sexual health Sensoa (sensoa.be).
Building on its vision to create a better and healthier every day for every woman, Organon launches survey results but also a video to challenge and help reduce stigma of global public health issue. “There is still so much we can do across our global and local communities to help raise awareness about unplanned pregnancy and work collectively towards lowering the rates,” says Petra Willems. “Today marks the beginning of a new conversation, one that is geared towards reducing the stigma of unplanned pregnancy and giving women the information that they need to make informed decisions.”
The video will be distributed on social media through Organon Benelux Vimeo, LinkedIn and Twitter channels and is available on HereforHerHealth.com where people are encouraged to share their perspective on how to help reduce unplanned pregnancy. Organon also invites women, their families, healthcare professionals and policy makers to visit https://hereforherhealth.com/unplanned/ to share their perspectives on how to help reduce the rates of unplanned pregnancy and join us on a collective mission of having the conversation.
1) RWB1443 Broadcast Revolution World Contraceptive Day Belgium research top-line chart, Q2-Have you ever had an unplanned pregnancy whilst taking contraceptives? 2) RWB1443 Broadcast Revolution World Contraceptive Day Belgium research top-line chart, Q3-How did the unplanned pregnancy affect your life? 3) RWB1443 Broadcast Revolution World Contraceptive Day Belgium research top-line chart, Q5-Would you consider using a different form of contraception?
4) RWB1443 Broadcast Revolution World Contraceptive Day Netherlands research top-line chart; Q2-Have you ever had an unplanned pregnancy whilst taking contraceptives? 5) RWB1443 Broadcast Revolution World Contraceptive Day Netherlands research top-line chart; Q3-How did the unplanned pregnancy affect your life? 6) RWB1443 Broadcast Revolution World Contraceptive Day Netherlands research top-line chart; Q5-Would you consider using a different form of contraception?
7) RWB1443 Broadcast Revolution World Contraceptive Day UK research top-line chart; Q2-Have you ever had an unplanned pregnancy whilst taking contraceptives? 8) RWB1443 Broadcast Revolution World Contraceptive Day UK research top-line chart; Q3-How did the unplanned pregnancy affect your life? 9) RWB1443 Broadcast Revolution World Contraceptive Day UK research top-line chart: Q5-Would you consider using a different form of contraception?
10) Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6
11) Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards meeting women’s contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med 17(2): e1003026. https://doi.org/10.1371/journal.pmed.1003026 **According to Kantorová et. al, modern methods of contraception include female and male sterilization, the intrauterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the lactational amenorrhea method (LAM), emergency contraception and other modern methods such as the contraceptive patch or vaginal ring.
OSS – Two months ago, we proudly announced that drug company MSD had taken the initiative for a special ode to women’s health. From three designs, the people from Oss convincingly chose RoosArt’s painting, which is entitled ‘The Pride of Oss’: an ode to women’s health, history and innovation. A lot has happened since then. Rosalie de Graaf will put the finishing touches to the enormous mural on Friday 2 July. The Oss manufacturing site has now been split off from MSD: on June 3 the name Organon returned and since then the name Organon has been displayed again on a number of the company buildings in Oss. After the mural has been completed, the name will also quickly return on the blue wall: a well-known name for a new company.
Are you curious how RoosArt made the beautiful artwork? Then watch the ‘making of’ video.
The characteristic, ribbed, blue wall was placed against the factory wall of the former Organon in the early seventies. The wall needs to be replaced in a few years, but has become a household name in Oss and surroundings. The blue wall symbolizes the many innovations that have been made in Oss in the field of women’s health. In the run-up to the split MSD-Organon, MSD invited three artists to make a move for the mural and presented the designs to the Ossetians.
Executive ‘mural artist’ RoosArt talks about her design: “My design is based on nature, where medicine originates. The tree symbolizes the basis of the company, which deals with different specializations, different branches. The three people in the design symbolize research, development and production. The painting gives a look inside the factory and shows the people with the right protective clothing. The bees in the design refer to the flowers and the bees. In the early 60s, a revolution started here in Oss thanks to the introduction of the contraceptive pill and the company is still working on solutions for women’s health in an innovative way.”
In response to the choice for ‘The Pride of Oss’, Wenny Raaijmakers, plant manager Organon Oss, says: “The wall has become a real icon over the years and belongs to the city, according to the inhabitants .” Generations of them have worked at the company, which has been on that spot since 1923. “And the people in Oss are proud of that. We are therefore pleased that three thousand inhabitants have made their voices heard.”
HEIST-OP-DEN-BERG – The launch of the Organon manufacturing site in Heist-op-den-Berg on June 9 was a great opportunity to show Organon’s commitment to improve women’s health. The site has a history of almost 50 years and is now part of Organon, since the worldwide launch of the new company on June 3.
On behalf of Organon Francois Marivoet (plant manager Organon Heist) and Petra Willems (managing director Organon Benelux) introduced the company to stakeholders and media. Guests at the opening meeting were Claire Tillekaerts (CEO Flanders Invest & Trade, right on the photo above) and Luc Vleugels, Mayor of Heist-op-den-Berg (left on the photo).
Organon in the Benelux hosts about 20 percent of all Organon employees and two out of six Organon production sites. In the modern Organon facilities in Heist-op-den-Berg (Belgium) 160 million packages are produced annually for patients in more than 140 countries. Of the more than 2.000 Organon employees that are based in the Benelux, about 900 work in Heist.
The main focus of Organon’s business is on women’s health. The Heist facility is specialized in modern manufacturing and packaging of tablets, sterile products, liquids, ointments and creams (established brands) and packaging of biotech products from other sites.
This is what the media published about the ‘launch’ of Organon in Heist:
BRUSSEL – Media in the Netherlands and Belgium have paid extensive attention to the return of the name Organon. On June 3, Organon (NYSE:OGN) celebrated its launch worldwide as the only company to focus on women’s health on such a large scale. In the Netherlands and Belgium, Organon has two production locations and two offices. Because the opening of the offices is only planned after the summer, the media came to Oss and Heist-op-den-Berg.
This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.